Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with Recludix

As Sanofi expands the reach of its blockbuster Dupixent, the French Big Pharma is looking to go further downstream in the IL-13 and IL-4 space with more inflammation and immunology drugs. It’s doling out $125 million in upfront payments to Recludix Pharma to do so. This is Sanofi’s second preclinical collaboration of the week, following a sickle cell disease tie-up with Scribe Therapeutics.